Newbury Pharmaceuticals AB (FRA:P52) Intangible Assets: €2.83 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:P52 Newbury Pharmaceuticals AB FRA:P52
42 GF Score
Price €0.16
GF Value €0.20
! 6 Warning Signs
View Full Analysis

What is Newbury Pharmaceuticals AB Intangible Assets?

Newbury Pharmaceuticals AB FRA:P52 -10.37% 42 Intangible Assets is €2.83 Mil as of Feb. 2026. GuruFocus rates FRA:P52 with a GF Score™ of 42/100 and a GF Value™ of €0.20. The stock has 6 warning signs investors should review.

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Newbury Pharmaceuticals AB's intangible assets for the quarter that ended in Feb. 2026 was €2.83 Mil.


Newbury Pharmaceuticals AB  (FRA:P52) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Newbury Pharmaceuticals AB Intangible Assets Related Terms


Newbury Pharmaceuticals AB Intangible Assets Historical Data

* Premium members only.

The historical data trend for Newbury Pharmaceuticals AB's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newbury Pharmaceuticals AB Intangible Assets Chart

Newbury Pharmaceuticals AB Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Intangible Assets
2.65 4.80 3.87 4.09 2.77

Newbury Pharmaceuticals AB Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.17 4.33 2.77 2.76 2.83
FRA:P52
42GF Score
Newbury Pharmaceuticals AB FRA:P52
Intangible Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newbury Pharmaceuticals AB Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Frequently Asked Questions Learn more about Intangible Assets →
What does a Intangible Assets of €2.83 Mil mean?
Newbury Pharmaceuticals AB (FRA:P52) has a Intangible Assets of €2.83 Mil as of Feb. 2026. Intangible assets include patents, goodwill and trade secrets. View historical data on Newbury Pharmaceuticals AB and its competitors.
Is Newbury Pharmaceuticals AB's Intangible Assets too high?
Newbury Pharmaceuticals AB's current Intangible Assets is €2.83 Mil. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Intangible Assets compare to ZTS and UTHR?
Newbury Pharmaceuticals AB's Intangible Assets of €2.83 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Drug Manufacturers company?
A good Intangible Assets depends on the Drug Manufacturers industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on Newbury Pharmaceuticals AB and its competitors. Newbury Pharmaceuticals AB's current Intangible Assets is €2.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Newbury Pharmaceuticals AB (FRA:P52) has a current Intangible Assets of €2.83 Mil. The stock's GF Value™ is €0.20, compared to a current price of €0.16 — trading 22.3% below its estimated fair value. The current Intangible Assets is €2.83 Mil. Newbury Pharmaceuticals AB's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (FRA:P52), the current Intangible Assets is €2.83 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newbury Pharmaceuticals AB (FRA:P52) Overvalued in 2026?

Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued. The current stock price of €0.16 is trading 22.3% below its estimated GF Value™ of €0.20.

Key valuation signals for FRA:P52:

  • Intangible Assets: €2.83 Mil
  • GF Value™: €0.20 vs. price of €0.16 (22.3% below fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the FRA:P52 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Newbury Pharmaceuticals AB Business Description

Other Exchanges NEWBRY:Sweden
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
42GF Score

Get the complete analysis for FRA:P52

Intangible Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price
€0.20
GF Value